AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aquestive Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.83+0.05 (+1.32%)
Close on Oct 19, 2026
- Market cap
- $478.73M
- P/E (TTM)
- –
- Dividend yield
- –
Aquestive Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Market Cap | $480.71M | $166.30M |
| Enterprise Value | $432.91M | $88.19M |
| PS Ratio | 8.89 | 3.65 |
Enterprise value
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 8.00 | 2.51 |
Income (trailing twelve months)
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Revenue | $54.09M | $58.34M |
| Gross Profit | $36.26M | $105.94M |
| Operating Income | -$52.75M | -$21.40M |
| Pretax Income | -$78.23M | -$14.34M |
| Net Income | -$78.23M | -$22.46M |
| EBITDA | -$52.23M | -$16.91M |
| EPS (Diluted) | -$0.65 | -$0.83 |
Margins
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 67.0% | 52.9% |
| Operating Margin | -97.5% | -44.0% |
| Pretax Margin | -144.6% | -13.3% |
| Profit Margin | -144.6% | -40.2% |
| EBITDA Margin | -96.6% | -30.2% |
| FCF Margin | -85.0% | -9.27% |
Returns
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -69.3% | -40.9% |
| Return on Capital Employed (ROCE) | -45.6% | -38.1% |
Growth
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 22.6% | 5.96% |
| Revenue Growth (3Y CAGR) | -2.24% | 2.25% |
| Revenue Growth (5Y CAGR) | -0.58% | 6.48% |
Balance sheet
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $98.49M | $61.43M |
| Total Debt | $50.69M | $118.52M |
| Net Cash (Debt) | $47.80M | $15.35M |
| Net Cash Per Share | $0.38 | $0.66 |
| Equity (Book Value) | -$56.59M | $49.09M |
| Book Value Per Share | -$0.45 | $1.37 |
| Tangible Book Value | -$56.59M | $23.52M |
| Working Capital | $102.02M | $76.81M |
Financial position
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 7.19 | 3.34 |
| Quick Ratio | 6.54 | 2.44 |
| Interest Coverage | -4.68 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$45.37M | -$12.35M |
| Capital Expenditures | -$584.00K | -$1.08M |
| Free Cash Flow | -$45.95M | -$20.22M |
| FCF Per Share | -$0.37 | -$0.42 |
Efficiency
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.48 | 0.39 |
| Inventory Turnover | 2.30 | 2.70 |
| Revenue Per Employee | $367.94K | $404.87K |
| Profits Per Employee | -$532.16K | -$703.34K |
| Employee Count | 147 | 74 |
Dividends and yields
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -16.3% | -23.3% |
| FCF Yield | -9.56% | -8.72% |
Shares
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 125,512,000 | 58,127,000 |
| Shares Change (YoY) | 27.4% | 10.9% |
| Shares Change (QoQ) | 0.99% | 0.54% |
| Float | 121,576,000 | 49,136,700 |
| Shares Held by Insiders | 3.14% | 11.6% |
| Shares Held by Institutions | 57.4% | 59.4% |
Taxes
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Aquestive Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -3.52 | -0.22 |
| Piotroski F-Score | 2 | 4 |
| Beneish M-Score | -1.88 | -2.62 |
Calculated by StockData from Aquestive Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.